An alternative method to analyse the biomarker‐strategy design. (9th September 2018)

• Record Type: Journal Article
• Authors: Kunz, Cornelia Ursula; Jaki, Thomas; Stallard, Nigel
• Is Part Of: Statistics in medicine. Volume 37:Number 30(2018)
• Page Start: 4636
• Page End: 4651
• Publication Date: 2018-09-09
• Subjects: analysis strategy -- biomarker -- design -- interaction -- personalised medicine; Medical statistics -- Periodicals; Statistique médicale -- Périodiques; Statistiques médicales -- Périodiques; 610.727
• DOI: 10.1002/sim.7940
• Languages: English
• ISSNs: 0277-6715

Abstract

Abstract : Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identification of subgroups of patients responding well to a treatment. One currently used clinical trial design incorporating a predictive biomarker is the so‐called biomarker strategy design (or marker‐based strategy design). Conventionally, the results from this design are analysed by comparing the mean of the biomarker‐led arm with the mean of the randomised arm. Several problems regarding the analysis of the data obtained from this design have been identified in the literature. In this paper, we show how these problems can be resolved if the sample sizes in the subgroups fulfil the specified orthogonality condition. We also propose a different analysis strategy that allows definition of test statistics for the biomarker‐by‐treatment interaction effect as well as for the classical treatment effect and the biomarker effect. We derive equations for the sample size calculation for the case of perfect and imperfect biomarker assays. We also show that the often used 1:1 randomisation does not necessarily lead to the smallest sample size. In addition, we provide point estimators and confidence intervals for the treatment effects in the subgroups. Application of our method is illustrated using a real data example.